Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 22, 2025Frontiers in OncologyOpen Access

Preoperative radiotherapy in patients with locally advanced esophageal squamous cell carcinoma: a narrative review

View Full Paper
Ask AI
Bookmark
Share

Authors

YLYan LinSWShoufeng WangHLHuan-Wei Liang

Discussion

Loading...

Member takes

Overview

Narrative review highlights neoadjuvant treatments and survival outcomes in patients with esophageal cancer, indicating importance of ongoing trials.

Key Points

  • Neoadjuvant treatments significantly improve survival rates in patients with locally advanced esophageal squamous cell carcinoma.
  • CROSS and NEOCRTEC5010 trials report enhanced survival with neoadjuvant chemoradiotherapy over surgery alone.
  • Recent trials show neoadjuvant triplet chemotherapy offers statistically significant overall survival benefits. Neoadjuvant immunotherapy exhibits higher histological complete response rates than chemotherapy.
  • Ongoing research is essential to clarify the role of radiotherapy and establish definitive treatment protocols as techniques evolve.

Cite This Study

Lin et al. (2025) studied this question.

synapsesocial.com/papers/689a0614e6551bb0af8cd73ehttps://doi.org/10.3389/fonc.2025.1613954
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Editorial: The role of adjuvant and neoadjuvant therapy in resectable esophageal cancer2025
  2. 2Neoadjuvant Chemoradiation versus Perioperative Chemotherapy in Locally Advanced Resectable Esophageal Adenocarcinoma: A National Analysis.2026
  3. 3150. NEOADJUVANT CHEMOIMMUNOTHERAPY WITH ADAPTIVE RADIOTHERAPY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA: STUDY PROTOCOL FOR A PROSPECTIVE MULTICENTER PHASE II TRIAL2025
  4. 4236. SAFETY AND EFFICACY OF CAMRELIZUMAB COMBINED WITH RADIOTHERAPY AS NEOADJUVANT THERAPY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA2025
  5. 5135. COMPARISON BETWEEN NEOADJUVANT-CHEMORADIOTHERAPY FOLLOWED BY SURGERY AND DEFINITIVE CHEMORADIOTHERAPY FOR SURVIVAL IN PATIENTS WITH RESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA (JCOG2305A)2025